Thursday, Jun 20, 2013 1:24am EDT
CRTX - Cornerstone Therapeutics Inc - Insider Transactions
SEC Form 4 |
Date |
Sym |
Company |
Insider |
Title |
Shares |
Transaction |
Value |
|---|---|---|---|---|---|---|---|---|
May 6 2013 | CRTX | Cornerstone Therapeutics Inc | Maetzel Andreas | VP, Clinical, Regulatory | 25,000 | Grant at $0.00 | $0 | |
Mar 7 2013 | CRTX | Cornerstone Therapeutics Inc | Duarte IRA | Principal Accounting Officer | 7,000 | Grant at $0.00 | $0 | |
Mar 5 2013 | CRTX | Cornerstone Therapeutics Inc | Powell Andrew Kenneth William | EVP, General Counsel | 21,375 | Grant at $0.00 | $0 | |
Mar 5 2013 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Strategy, Bus. Dev. | 25,000 | Grant at $0.00 | $0 | |
Mar 5 2013 | CRTX | Cornerstone Therapeutics Inc | Roberts Alan | VP, Scientific Affairs | 18,375 | Grant at $0.00 | $0 | |
Mar 5 2013 | CRTX | Cornerstone Therapeutics Inc | McBean Kenneth | President | 40,000 | Grant at $0.00 | $0 | |
Mar 5 2013 | CRTX | Cornerstone Therapeutics Inc | Collard Craig A | CEO | 45,000 | Grant at $0.00 | $0 | |
Jan 17 2013 | CRTX | Cornerstone Therapeutics Inc | McBean Kenneth | President | 1,217 | Option payment at $5.58 | $6,791 | |
Nov 6 2012 | CRTX | Cornerstone Therapeutics Inc | McEwan Alastair Stuart | CFO, Treasurer | 50,000 | Grant at $0.00 | $0 | |
Nov 5 2012 | CRTX | Cornerstone Therapeutics Inc | McBean Kenneth | President | 1,022 | Option payment at $4.85 | $4,957 | |
Sep 10 2012 | CRTX | Cornerstone Therapeutics Inc | Powell Andrew Kenneth William | EVP, General Counsel | 2,045 | Option payment at $6.27 | $12,822 | |
Sep 6 2012 | CRTX | Cornerstone Therapeutics Inc | McBean Kenneth | President | 4,056 | Option payment at $6.30 | $25,553 | |
Aug 29 2012 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Strategy, Bus. Dev. | 38,637 | Option exercise at $3.90 | $150,684 | |
Aug 29 2012 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Strategy, Bus. Dev. | 38,637 | Sale at $6.86 | $265,050 | |
Aug 24 2012 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Strategy, Bus. Dev. | 24,688 | Option exercise at $3.90 | $96,283 | |
Aug 24 2012 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Strategy, Bus. Dev. | 24,688 | Sale at $7.01 | $173,063 | |
Aug 22 2012 | CRTX | Cornerstone Therapeutics Inc | Morgus Vincent T. | EVP, Finance, CFO | 847 | Option payment at $7.22 | $6,115 | |
May 28 2012 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Strategy, Bus. Dev. | 4,056 | Option payment at $5.04 | $20,442 | |
Jun 19 2012 | CRTX | Cornerstone Therapeutics Inc | Morgus Vincent T. | EVP, Finance, CFO | 787 | Option payment at $5.94 | $4,675 | |
May 25 2012 | CRTX | Cornerstone Therapeutics Inc | Roberts Alan | VP, Scientific Affairs | 5,678 | Option payment at $5.04 | $28,617 | |
Apr 3 2012 | CRTX | Cornerstone Therapeutics Inc | Chiesi Farmaceutici Spa | 10% Owner | 1,443,913 | Purchase at $6.25 | $9,024,456 | |
Apr 3 2012 | CRTX | Cornerstone Therapeutics Inc | Collard Craig A | CEO, 10% Owner | 1,443,913 | Sale at $6.25 | $9,024,456 | |
MMar 14 2012 | CRTX | Cornerstone Therapeutics Inc | Chiesi Farmaceutici Spa | 10% Owner | 6,800 | Purchase at $6.04 | $41,038 | |
MMar 14 2012 | CRTX | Cornerstone Therapeutics Inc | Chiesi Farmaceutici Spa | 10% Owner | 6,800 | Purchase at $6.04 | $41,038 | |
Mar 12 2012 | CTRX | Cornerstone Therapeutics Inc | Chiesi Farmaceutici Spa | 10% Owner | 3,400 | Purchase at $5.85 | $19,885 | |
Feb 1 2012 | CRTX | Cornerstone Therapeutics Inc | Morgus Vincent T. | EVP, Finance, CFO | 3,722 | Option payment at $6.48 | $24,119 | |
Dec 14 2011 | CTRX | Cornerstone Therapeutics Inc | Chiesi Farmaceutici Spa | 10% Owner | 2,100 | Grant at $5.12 | $10,750 | |
Nov 29 2011 | CTRX | Cornerstone Therapeutics Inc | Chiesi Farmaceutici Spa | 10% Owner | 8,900 | Grant at $5.06 | $45,078 | |
Sep 6 2011 | CRTX | Cornerstone Therapeutics Inc | McBean Kenneth | President | 50,000 | Grant at $0.00 | $0 | |
Jul 15 2011 | CRTX | Cornerstone Therapeutics Inc | Powell Andrew Kenneth William | EVP, General Counsel | 2,000 | Sale at $8.63 | $17,260 | |
May 26 2011 | CRTX | Cornerstone Therapeutics Inc | Roberts Alan | VP, Scientific Affairs | 5,850 | Sale at $7.60 | $44,460 | |
Apr 4 2011 | CRTX | Cornerstone Therapeutics Inc | Powell Andrew Kenneth William | EVP, General Counsel | 2,000 | Sale at $6.53 | $13,060 | |
Feb 1 2011 | CRTX | Cornerstone Therapeutics Inc | Morgus Vincent T. | EVP, Finance, CFO | 55,000 | Grant at $0.00 | $0 | |
Jan 7 2011 | CRTX | Cornerstone Therapeutics Inc | Powell Andrew Kenneth William | EVP, General Counsel | 2,000 | Sale at $5.73 | $11,460 | |
Dec 16 2010 | CRTX | Cornerstone Therapeutics Inc | Lutz Steven Michael | EVP | 65,000 | Sale at $6.02 | $391,300 | |
Dec 16 2010 | CRTX | Cornerstone Therapeutics Inc | Collard Craig A | President, CEO, 10% Owner | 385,000 | Sale at $6.02 | $2,317,700 | |
Dec 16 2010 | CRTX | Cornerstone Therapeutics Inc | Chiesi Farmaceutici Spa | 10% Owner | 450,000 | Grant at $6.02 | $2,709,000 | |
Nov 1 2010 | CRTX | Cornerstone Therapeutics Inc | Powell Andrew Kenneth William | EVP, General Counsel | 7,900 | Sale at $6.28 | $49,612 | |
Jun 1 2010 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Sales, Marketing | 4,129 | Sale at $5.47 | $22,586 | |
Oct 14 2009 | CRTX | Cornerstone Therapeutics Inc | Chiesi Farmaceutici Spa | 10% Owner | 269,684 | Grant at $0.00 | $0 | |
Oct 30 2009 | CRTX | Cornerstone Therapeutics Inc | Powell Andrew Kenneth William | EVP, General Counsel | 110,000 | Grant at $0.00 | $0 | |
MSep 10 2009 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Sales, Marketing | 8,100 | Option exercise at $3.90 | $31,590 | |
MSep 10 2009 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Sales, Marketing | 8,100 | Sale at $7.54 | $61,081 | |
MSep 1 2009 | CRTX | Cornerstone Therapeutics Inc | Price David | CFO | 150,000 | Sale at $7.05 | $1,057,235 | |
Sep 2 2009 | CRTX | Cornerstone Therapeutics Inc | Dickson Brian | Chief Medical Officer | 15,000 | Sale at $6.74 | $101,100 | |
Jul 28 2009 | CRTX | Cornerstone Therapeutics Inc | Lutz Steven Michael | EVP | 350,000 | Sale at $5.50 | $1,925,000 | |
Jul 28 2009 | CRTX | Cornerstone Therapeutics Inc | Cornerstone Biopharma Holdings, Ltd. | 10% Owner | 1,250,000 | Sale at $5.50 | $6,875,000 | |
Jul 28 2009 | CRTX | Cornerstone Therapeutics Inc | Collard Craig A | President, CEO, 10% Owner | 1,250,000 | Sale at $5.50 | $6,875,000 | |
Jun 19 2009 | CRTX | Cornerstone Therapeutics Inc | McEwan Alastair Stuart | Director | 8,141 | Sale at $9.00 | $73,269 | |
MJun 12 2009 | CRTX | Cornerstone Therapeutics Inc | McEwan Alastair Stuart | Director | 46,704 | Sale at $8.51 | $397,451 | |
MJun 10 2009 | CRTX | Cornerstone Therapeutics Inc | McEwan Alastair Stuart | Director | 7,165 | Sale at $8.50 | $60,903 | |
MJun 5 2009 | CRTX | Cornerstone Therapeutics Inc | McEwan Alastair Stuart | Director | 57,031 | Sale at $8.08 | $460,545 | |
May 29 2009 | CRTX | Cornerstone Therapeutics Inc | Dickson Brian | Chief Medical Officer | 15,000 | Option exercise at $0.43 | $6,450 | |
May 28 2009 | CRTX | Cornerstone Therapeutics Inc | Franklin Joshua B | VP, Sales, Marketing | 50,000 | Grant at $0.00 | $0 | |
May 18 2009 | CRTX | Cornerstone Therapeutics Inc | McEwan Alastair Stuart | Director | 119,041 | Option exercise at $0.43 | $51,188 | |
MMay 14 2009 | CRTX | Cornerstone Therapeutics Inc | Townsend Scott B | GENERAL COUNSEL, EVP LEGAL | 44,972 | Sale at $6.48 | $291,635 | |
Nov 14 2008 | CRTX | Cornerstone Therapeutics Inc | Young Jeffrey E | FORMER VP FINANCE, CAO | 220 | Option payment at $3.50 | $770 | |
Oct 31 2008 | CRTX | Critical Therapeutics Inc | Baldwin Chenyqua Michele | VP Finance | 178,562 | Grant at $0.00 | $0 | |
Oct 31 2008 | CRTX | Critical Therapeutics Inc | Price David | CFO | 325,133 | Grant at $0.00 | $0 | |
Oct 31 2008 | CRTX | Critical Therapeutics Inc | Lutz Steven Michael | EVP | 677,348 | Grant at $0.00 | $0 | |
MOct 31 2008 | CRTX | Critical Therapeutics Inc | Collard Craig A | President, CEO, 10% Owner | 4,646,138 | Grant at $0.00 | $0 | |
Oct 31 2008 | CRTX | Critical Therapeutics Inc | Townsend Scott B | GENERAL COUNSEL, EVP LEGAL | 193 | Option payment at $3.90 | $753 | |
Nov 3 2008 | CRTX | Critical Therapeutics Inc | Townsend Scott B | GENERAL COUNSEL, EVP LEGAL | 148,722 | Grant at $0.00 | $0 | |
Oct 31 2008 | CRTX | Critical Therapeutics Inc | Young Jeffrey E | FORMER VP FINANCE, CAO | 193 | Option payment at $3.90 | $753 | |
Oct 31 2008 | CRTX | Critical Therapeutics Inc | Phillips Trevor | Former President, CEO | 507 | Option payment at $3.90 | $1,977 | |
Feb 14 2008 | CRTX | Critical Therapeutics Inc | Townsend Scott B | GENERAL COUNSEL, SVP LEGAL | 35,000 | Grant at $0.00 | $35 | |
Feb 14 2008 | CRTX | Critical Therapeutics Inc | Kelly Thomas Patrick | CFO, SVP Finance, Corp. Dev, | 35,000 | Grant at $0.00 | $35 | |
Dec 27 2007 | CRTX | Critical Therapeutics Inc | Young Jeffrey E | VP FINANCE, CAO, TREASURER | 4,270 | Option payment at $1.28 | $5,466 | |
Dec 27 2007 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 5,598 | Option payment at $1.28 | $7,165 | |
Dec 27 2007 | CRTX | Critical Therapeutics Inc | Townsend Scott B | GENERAL COUNSEL, SVP LEGAL | 4,270 | Option payment at $1.28 | $5,466 | |
Nov 5 2007 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 50,000 | Grant at $0.00 | $50 | |
Nov 5 2007 | CRTX | Critical Therapeutics Inc | Kelly Thomas Patrick | CFO, SVP Finance, Corp. Dev, | 25,000 | Grant at $0.00 | $25 | |
Nov 5 2007 | CRTX | Critical Therapeutics Inc | Townsend Scott B | GENERAL COUNSEL, SVP LEGAL | 25,000 | Grant at $0.00 | $25 | |
Nov 5 2007 | CRTX | Critical Therapeutics Inc | Young Jeffrey E | VP FINANCE, CAO, TREASURER | 25,000 | Grant at $0.00 | $25 | |
MAug 22 2007 | CRTX | Critical Therapeutics Inc | Thomas Frank E | President, CEO | 5,000 | Purchase at $2.12 | $10,620 | |
Aug 22 2007 | CRTX | Critical Therapeutics Inc | Kelly Thomas Patrick | CFO, SVP Finance, Corp. Dev, | 4,000 | Purchase at $2.08 | $8,320 | |
Aug 20 2007 | CRTX | Critical Therapeutics Inc | Kelly Thomas Patrick | CFO, SVP Finance, Corp. Dev, | 26,700 | Grant at $0.00 | $27 | |
Jun 25 2007 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 1,389 | Option exercise at $0.38 | $528 | |
Jun 14 2007 | CRTX | Critical Therapeutics Inc | Tananbaum James B | Director | 195,751 | Sale at $2.29 | $448,681 | |
Jun 13 2007 | CRTX | Critical Therapeutics Inc | Thomas Frank E | President, CEO | 1,500 | Grant at $2.24 | $3,360 | |
MJun 11 2007 | CRTX | Critical Therapeutics Inc | Tananbaum James B | Director | 363,310 | Sale at $2.26 | $819,982 | |
MJun 6 2007 | CRTX | Critical Therapeutics Inc | Tananbaum James B | Director | 619,794 | Sale at $2.60 | $1,612,624 | |
Jun 6 2007 | CRTX | Critical Therapeutics Inc | Thomas Frank E | President, CEO | 1,500 | Grant at $2.69 | $4,035 | |
MJun 1 2007 | CRTX | Critical Therapeutics Inc | Tananbaum James B | Director | 1,102,167 | Sale at $2.78 | $3,060,908 | |
Jun 4 2007 | CRTX | Critical Therapeutics Inc | Thomas Frank E | President, CEO | 2,000 | Grant at $2.75 | $5,500 | |
May 31 2007 | CRTX | Critical Therapeutics Inc | Townsend Scott B | GENERAL COUNSEL, SVP LEGAL | 11,438 | Other Purchase at $1.59 | $18,186 | |
May 31 2007 | CRTX | Critical Therapeutics Inc | Young Jeffrey E | VP FINANCE, CAO, TREASURER | 3,039 | Other Purchase at $1.59 | $4,832 | |
May 31 2007 | CRTX | Critical Therapeutics Inc | Thomas Frank E | President, CEO | 2,148 | Other Purchase at $1.59 | $3,415 | |
Feb 13 2007 | CRTX | Critical Therapeutics Inc | Evnin Luke | Former 10% Owner | 7,226 | Other Purchase at $0.00 | $0 | |
Feb 13 2007 | CRTX | Critical Therapeutics Inc | Gadicke Ansbert | Former 10% Owner | 1,204 | Other Purchase at $0.00 | $0 | |
Feb 13 2007 | CRTX | Critical Therapeutics Inc | Steinmetz Michael | Former 10% Owner | 723 | Other Purchase at $0.00 | $0 | |
Feb 13 2007 | CRTX | Critical Therapeutics Inc | Wheeler Kurt | Former 10% Owner | 452 | Other Purchase at $0.00 | $0 | |
MFeb 13 2007 | CRTX | Critical Therapeutics Inc | Galakatos Nicholas | Director | 963 | Other Purchase at $0.00 | $0 | |
Feb 13 2007 | CRTX | Critical Therapeutics Inc | Walsh Christopher T Phd | Director | 325 | Other Purchase at $0.00 | $0 | |
Feb 13 2007 | CRTX | Critical Therapeutics Inc | Mpm Bioventures II Qp LP | Former 10% Owner | 1,000,000 | Other Sale at $0.00 | $0 | |
Feb 13 2007 | CRTX | Critical Therapeutics Inc | Galakatos Nicholas | Director | 1,000,000 | Other Sale at $0.00 | $0 | |
Dec 27 2006 | CRTX | Critical Therapeutics Inc | Thomas Frank E | President, CEO | 40,000 | Grant at $40.00 | $1,600,000 | |
Dec 27 2006 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 35,000 | Grant at $35.00 | $1,225,000 | |
Dec 27 2006 | CRTX | Critical Therapeutics Inc | Hilt Dana Charles | SVP of Clinical Develop., CMO | 26,700 | Grant at $26.70 | $712,890 | |
Dec 27 2006 | CRTX | Critical Therapeutics Inc | Townsend Scott B | GENERAL COUNSEL , VP LEGAL | 26,700 | Grant at $26.70 | $712,890 | |
Dec 27 2006 | CRTX | Critical Therapeutics Inc | Young Jeffrey E | VP FINANCE, CAO, TREASURER | 26,700 | Grant at $26.70 | $712,890 | |
Nov 30 2006 | CRTX | Critical Therapeutics Inc | Thomas Frank E | President | 1,885 | Other Purchase at $1.66 | $3,129 | |
Aug 8 2006 | CRTX | Critical Therapeutics Inc | Thomas Frank E | President | 4,000 | Grant at $3.90 | $15,600 | |
MAug 8 2006 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 14,500 | Sale at $4.01 | $58,210 | |
Aug 9 2006 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 10,500 | Option exercise at $1.05 | $11,025 | |
Apr 25 2006 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $5.24 | $41,900 | |
Apr 6 2006 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 21,356 | Option exercise at $1.05 | $22,424 | |
MMar 28 2006 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $5.02 | $40,181 | |
Mar 22 2006 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 72,933 | Option exercise at $0.38 | $27,715 | |
Mar 14 2006 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $5.57 | $44,544 | |
Mar 6 2006 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 5,000 | Option exercise at $1.05 | $5,250 | |
MMar 6 2006 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 2,500 | Sale at $6.00 | $15,001 | |
MFeb 28 2006 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $5.42 | $43,368 | |
Jan 24 2006 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $5.25 | $42,032 | |
Feb 1 2006 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 2,500 | Option exercise at $1.05 | $2,625 | |
Feb 1 2006 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 2,500 | Sale at $6.42 | $16,050 | |
MJan 30 2006 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $6.54 | $32,688 | |
MJan 24 2006 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $6.29 | $50,330 | |
MJan 17 2006 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $6.70 | $33,497 | |
MJan 10 2006 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $6.73 | $53,868 | |
MJan 3 2006 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $7.12 | $35,622 | |
Jan 3 2006 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 3,333 | Option exercise at $0.38 | $1,267 | |
MJan 3 2006 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 1,944 | Sale at $7.12 | $13,850 | |
MDec 27 2005 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $6.69 | $53,489 | |
MDec 15 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $6.72 | $33,622 | |
Dec 15 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 2,000 | Option exercise at $0.38 | $760 | |
Dec 15 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 2,000 | Gift at $0.00 | $0 | |
Dec 13 2005 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $6.75 | $53,960 | |
MDec 2 2005 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 5,000 | Sale at $6.26 | $31,325 | |
MNov 30 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $6.43 | $32,136 | |
MNov 22 2005 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $6.55 | $52,439 | |
MOct 31 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $7.01 | $35,043 | |
MOct 17 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $8.65 | $43,267 | |
MNov 15 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $6.78 | $33,922 | |
MNov 8 2005 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $7.55 | $60,410 | |
Nov 2 2005 | CRTX | Critical Therapeutics Inc | Thomas Frank E | CFO, SVP Finance, Treasurer | 1,000 | Option exercise at $5.63 | $5,630 | |
MNov 2 2005 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 5,000 | Sale at $6.57 | $32,873 | |
Oct 31 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $7.01 | $35,043 | |
MOct 25 2005 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $8.66 | $69,263 | |
MOct 11 2005 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $8.50 | $68,002 | |
Dec 17 2004 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 21,356 | Option exercise at $1.05 | $22,424 | |
Dec 19 2003 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 24,000 | Gift at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 1,000 | Purchase at $7.00 | $7,000 | |
Oct 17 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 5,000 | Sale at $8.65 | $43,267 | |
MOct 11 2005 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 8,000 | Sale at $8.50 | $68,002 | |
MOct 3 2005 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 5,000 | Sale at $9.05 | $45,258 | |
MSep 19 2005 | CRTX | Critical Therapeutics Inc | Finnegan Frederick | SVP of Sales, Marketing | 24,169 | Option exercise at $1.05 | $25,377 | |
Sep 21 2005 | CRTX | Critical Therapeutics Inc | Townsend Scott B | VP OF LEGAL AFFAIRS, SEC. | 1,000 | Option exercise at $4.84 | $4,840 | |
MSep 19 2005 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 5,000 | Sale at $5.90 | $29,520 | |
Sep 14 2005 | CRTX | Critical Therapeutics Inc | Thomas Frank E | CFO, SVP Finance, Treasurer | 1,000 | Option exercise at $5.63 | $5,630 | |
MSep 6 2005 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, SVP of Operations | 6,400 | Gift at $0.00 | $0 | |
MAug 22 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 19,400 | Gift at $0.00 | $0 | |
MAug 22 2005 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 19,400 | Gift at $0.00 | $0 | |
MJun 2 2004 | CRTX | Critical Therapeutics Inc | Mpm Bioventures II Qp LP | 10% Owner | 3,941,330 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Mpm Bioventures II Qp LP | 10% Owner | 357,100 | Purchase at $7.00 | $2,499,700 | |
MJun 20 2005 | CRTX | Critical Therapeutics Inc | Advanced Technology Ventures VII LP | 10% Owner | 1,277,373 | Purchase at $5.48 | $7,000,004 | |
MJun 20 2005 | CRTX | Critical Therapeutics Inc | George Jean | Director | 1,277,373 | Purchase at $5.48 | $7,000,004 | |
Jun 20 2005 | CRTX | Critical Therapeutics Inc | Galakatos Nicholas | Director, 10% Owner | 547,446 | Purchase at $5.48 | $3,000,004 | |
Jun 20 2005 | CRTX | Critical Therapeutics Inc | Mpm Bioventures II Qp LP | 10% Owner | 547,446 | Purchase at $5.48 | $3,000,004 | |
Jun 20 2005 | CRTX | Critical Therapeutics Inc | Miraelli Christopher | Director, 10% Owner | 1,094,891 | Purchase at $5.48 | $6,000,003 | |
MJun 2 2004 | CRTX | Critical Therapeutics Inc | Mpm Bioventures III Qp LP | 10% Owner | 3,941,330 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Mpm Bioventures III Qp LP | 10% Owner | 357,100 | Purchase at $7.00 | $2,499,700 | |
MJun 2 2004 | CRTX | Critical Therapeutics Inc | Galakatos Nicholas | Director, 10% Owner | 3,941,330 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Galakatos Nicholas | Director, 10% Owner | 357,100 | Purchase at $7.00 | $2,499,700 | |
Apr 28 2004 | CRTX | Critical Therapeutics Inc | Thomas Frank E | CFO, SVP Finance, Treasurer | 10,000 | Option exercise at $5.63 | $56,300 | |
Jan 25 2005 | CRTX | Critical Therapeutics Inc | Thomas Frank E | CFO, SVP Finance, Treasurer | 2,000 | Option exercise at $5.63 | $11,260 | |
Jan 25 2005 | CRTX | Critical Therapeutics Inc | Thomas Frank E | CFO, SVP Finance, Treasurer | 2,000 | Option exercise at $5.63 | $11,260 | |
MDec 22 2004 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 10,000 | Other Purchase at $0.00 | $0 | |
Dec 17 2004 | CRTX | Critical Therapeutics Inc | Warren Howland Shaw | Director | 21,356 | Option exercise at $1.05 | $22,424 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | George Jean | Director, 10% Owner | 1,904,759 | Converted deriv at $0.00 | $0 | |
MJun 2 2004 | CRTX | Critical Therapeutics Inc | Healthcare Ventures VI LP | 10% Owner | 3,701,332 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Healthcare Ventures VI LP | 10% Owner | 357,100 | Purchase at $7.00 | $2,499,700 | |
MJan 21 2004 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 106,664 | Option exercise at $0.40 | $42,791 | |
MJan 21 2004 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 164,662 | Gift at $0.00 | $0 | |
Jan 9 2004 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, VP of Operations, Sec. | 21,944 | Option exercise at $0.38 | $8,229 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Medimmune Ventures, Inc. | 10% Owner | 2,857,142 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | George Jean | Director, 10% Owner | 1,904,759 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Newman Walter | Chief Scientific Officer, VP R | 10,666 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Phillips Trevor | COO, VP of Operations, Sec. | 3,200 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Rubin Paul D | President, CEO | 92,570 | Converted deriv at $0.00 | $0 | |
MJun 2 2004 | CRTX | Critical Therapeutics Inc | Galakatos Nicholas | Director, 10% Owner | 3,941,330 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Galakatos Nicholas | Director, 10% Owner | 357,100 | Purchase at $7.00 | $2,499,700 | |
MJun 2 2004 | CRTX | Critical Therapeutics Inc | Mpm Bioventures III Qp LP | 10% Owner | 3,941,330 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Mpm Bioventures III Qp LP | 10% Owner | 357,100 | Purchase at $7.00 | $2,499,700 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Johnson & Johnson | 10% Owner | 1,961,904 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Johnson & Johnson | 10% Owner | 142,800 | Purchase at $7.00 | $999,600 | |
MJun 2 2004 | CRTX | Critical Therapeutics Inc | Healthcare Ventures VI LP | 10% Owner | 3,701,332 | Converted deriv at $0.00 | $0 | |
Jun 2 2004 | CRTX | Critical Therapeutics Inc | Healthcare Ventures VI LP | 10% Owner | 357,100 | Purchase at $7.00 | $2,499,700 |
D Derivative transaction exists
E Error filing
M Multiple transactions summarized; earliest reported transaction date and average weighted transaction price
Yahoo Finance